MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Bio-Techne Corp

Cerrado

SectorSalud

54.16 -0.4

Resumen

Variación precio

24h

Actual

Mínimo

53.84

Máximo

54.3

Métricas clave

By Trading Economics

Ingresos

-12M

23M

Ventas

19M

316M

P/B

Media del Sector

62.09

39.564

Rentabilidad por dividendo

0.62

Margen de beneficio

7.144

Empleados

3,100

EBITDA

-36M

39M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+20.39% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.62%

2.40%

Próximas Ganancias

6 ago 2025

Fecha Próximo Dividendo

29 ago 2025

Próxima Fecha de Ex Dividendo

18 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2.5B

8.1B

Apertura anterior

54.56

Cierre anterior

54.16

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

108 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Bio-Techne Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jul 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Principales Movimientos del Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Ganancias

BASF Cuts Outlook on Global Economy Uncertainty

12 jul 2025, 17:01 UTC

Ganancias

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 jul 2025, 14:53 UTC

Ganancias

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12 jul 2025, 02:24 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Adquisiciones, fusiones, absorciones

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Charlas de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Adquisiciones, fusiones, absorciones

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Charlas de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Charlas de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Charlas de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Charlas de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Charlas de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Ganancias

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Charlas de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Ganancias

BASF Will Publish Half-Year Results on July 30

11 jul 2025, 16:04 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

11 jul 2025, 16:04 UTC

Charlas de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 jul 2025, 16:03 UTC

Ganancias

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 jul 2025, 16:02 UTC

Ganancias

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 jul 2025, 16:01 UTC

Ganancias

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 jul 2025, 16:00 UTC

Ganancias

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 jul 2025, 15:59 UTC

Ganancias

BASF Cuts 2025 Earnings View

11 jul 2025, 15:58 UTC

Ganancias

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 jul 2025, 15:57 UTC

Ganancias

BASF 2Q EBIT Before Special Items EUR810M

11 jul 2025, 15:54 UTC

Ganancias

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Comparación entre iguales

Cambio de precio

Bio-Techne Corp Esperado

Precio Objetivo

By TipRanks

20.39% repunte

Estimación a 12 meses

Media 65.18 USD  20.39%

Máximo 80 USD

Mínimo 51 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bio-Techne Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

9

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

49.67 / 50.24Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

108 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.